Powered by

Opko Health purchases Bio-Reference Laboratories in a deal valued at $1.47B :

Jun 05, 2015 - The Deal Pipeline
Mergers and Acquisitions

Opko Health Inc. (OPK) announced on Thursday that it would purchase Bio-Reference Laboratories Inc. (BRLI) in a deal valued at $1.47 billion.

Bio-Reference is the third largest clinical laboratory in the United States. Under the terms of the agreement, Bio-Reference shareholders will receive 2.75 shares of Opko common stock for each share of Bio-Reference stock. The transaction is based on a closing price of $19.12 per share of OPKO stock, or $52.58 per share of Bio-Reference stock.